Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T78299	Amlitelimab		98%	Amlitelimab
T78299	Alvircept sudotox, an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb), disrupts the OX40-OX40L interaction and is used in atopic dermatitis research [1] [2] [...			Amlitelimab
T78300	Anivovetmab	2370896-63-0	98%	Anivovetmab
T78300	Anivovetmab (KIND-030), an IgG2 type monoclonal antibody targeting the VP2 protein (parvovirus major capsid), offers a potential research avenue for canine parvo...			Anivovetmab
T78301	Aselizumab	395639-53-9	98%	Aselizumab
T78301	Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that...			Aselizumab
T78302	Atacicept	845264-92-8	98%	Atacicept
T78302	Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human Ig...			Atacicept
T78303	Baminercept	909110-25-4	98%	Baminercept
T78303	Baminercept (BG 9924), an IgG fusion protein targeting the lymphotoxin β receptor (LTβR-Ig), has potential applications in the study of various autoimmune diseas...			Baminercept
T78304	Bapotulimab	2359413-58-2	98%	Bapotulimab
T78304	Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the immunoglobulin-like domain-containing receptor 2 (ILDR2), exhibiting antitumor and immu...			Bapotulimab
T78305	Briquilimab	2574591-89-0	98%	Briquilimab
T78305	Briquilimab (JSP-191), a non-toxic humanized monoclonal antibody, targets CD117 (c-Kit) to deplete hematopoietic stem cells (HSCs), providing a safe approach for...			Briquilimab
T78306	Ulenistamab	2415259-90-2	98%	Ulenistamab
T78306	Ulenistamab (PBP1510) is a first-in-class humanized IgG1 monoclonal antibody that targets the pancreatic adenocarcinoma upregulated factor (PAUF), and is utilize...			Ulenistamab
T78307	Catumaxomab	509077-98-9	98%	Catumaxomab
T78307	Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits aff...			Catumaxomab
T78308	Tenatumomab	1412891-40-7	98%	Tenatumomab
T78308	Tenatumomab (ST2146), a murine monoclonal antibody targeting tenascin-C—a largely overexpressed extracellular glycoprotein in cancer—facilitates Pretargeted Anti...			Tenatumomab
T78309	Telitacicept	2136630-26-5	98%	Telitacicept
T78309	Telitacicept (RC18), a fully human TACI-Fc fusion protein, acts as a dual inhibitor of B lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand)...			Telitacicept
T78310	Raxibacumab	565451-13-0	98%	Raxibacumab
T78310	Raxibacumab (ABthrax), a human IgG1 monoclonal antibody, targets the protective antigen (PA) of Bacillus anthracis. It inhibits the toxic impact of anthrax by ob...			Raxibacumab
T78311	Sontuzumab	372075-37-1	98%	Sontuzumab
T78311	Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for th...			Sontuzumab
T78312	Cifurtilimab	1629760-27-5	98%	Cifurtilimab
T78312	Cifurtilimab (SEA-CD40), a nonfucosylated humanized IgG1 monoclonal antibody with agonistic properties, targets the CD40 receptor and demonstrates antitumor acti...			Cifurtilimab
T78313	Fazpilodemab	2517935-02-1	98%	Fazpilodemab
T78313	Fazpilodemab (BFKB8488A) is a humanized agonistic bispecific antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. It is utilized in r...			Fazpilodemab
T78314	Fianlimab	2126132-98-5	98%	Fianlimab
T78314	Fianlimab (REGN3767) is a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T cells, exhibiting anti-tumor activity [1].			Fianlimab
T78315	Foravirumab	944548-38-3	98%	Foravirumab
T78315	Foravirumab (CR4098) is a monoclonal antibody targeting antigenic site III of the rabies virus glycoprotein [1].			Foravirumab
T78316	Frunevetmab	1708936-80-4	98%	Frunevetmab
T78316	Frunevetmab (NV-02), a felinized monoclonal antibody targeting nerve growth factor (NGF), exhibits a high affinity with a dissociation constant (Kd) of 20 pM and...			Frunevetmab
T78317	Blinatumomab	853426-35-4	98%	Blinatumomab
T78317	Blinatumomab (formerly known as Anatumomab) is a bispecific monoclonal antibody that specifically targets the CD19 antigen on B cells and is utilized in the stud...			Blinatumomab
T78318	Gatipotuzumab	1264737-26-9	98%	Gatipotuzumab
T78318	Gatipotuzumab (PankoMab), a humanized monoclonal antibody, targets the tumor-specific epitope TA-MUC1 of mucin-1 and exhibits potent tumor-specific antibody-depe...			Gatipotuzumab